Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids

• Published in: Rheumatology (Oxford, England) Vol. 52; no. 6; pp. 1058 - 1069
• Main Authors: Devogelaer, J.-P., Sambrook, P., Reid, D. M., Goemaere, S., Ish-Shalom, S., Collette, J., Su, G., Bucci-Rechtweg, C., Papanastasiou, P., Reginster, J.-Y.
• Format: Journal Article Web Resource
• Language: English
• Published: England Oxford University Press 01.06.2013
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Diphosphonates - administration & dosage; Diphosphonates - therapeutic use; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid - administration & dosage; Etidronic Acid - analogs & derivatives; Etidronic Acid - therapeutic use; Female; General & internal medicine; Glucocorticoids - adverse effects; Glucocorticoids - therapeutic use; Human health sciences; Humans; Imidazoles - administration & dosage; Imidazoles - therapeutic use; Infusions, Intravenous; Male; Middle Aged; Médecine générale & interne; Osteoporosis - chemically induced; Osteoporosis - drug therapy; Osteoporosis - prevention & control; Prednisone - adverse effects; Prednisone - therapeutic use; Risedronate Sodium; Sciences de la santé humaine; Treatment Outcome; glucocorticoid-induced osteoporosis; glucocorticoids; bone turnover markers; zoledronic acid; risedronate

Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turno...